Literature DB >> 14560714

Children in clinical research: a conflict of moral values.

Vera Hassner Sharav1.   

Abstract

This paper examines the culture, the dynamics and the financial underpinnings that determine how medical research is being conducted on children in the United States. Children have increasingly become the subject of experiments that offer them no potential direct benefit but expose them to risks of harm and pain. A wide range of such experiments will be examined, including a lethal heartburn drug test, the experimental insertion of a pacemaker, an invasive insulin infusion experiment, and a fenfluramine "violence prediction" experiment. Emphasis, however, is given to psychoactive drug tests because of the inherent ethical and diagnostic problems involved in the absence of any objective, verifiable diagnostic tool. Effort is made to provide readers comprehensive reference sources to evidence-based reports about the serious risks these drugs pose for adults and children so that the reader may judge whether the benefits (if any) outweigh the risks for children.

Entities:  

Keywords:  Biomedical and Behavioral Research; Legal Approach

Mesh:

Substances:

Year:  2003        PMID: 14560714     DOI: 10.1162/152651603322781639

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  3 in total

1.  Protection of children and adolescents in psychiatric research: an unfinished business.

Authors:  Antal E Solyom; Jonathan D Moreno
Journal:  HEC Forum       Date:  2005-09

2.  Body matters: rethinking the ethical acceptability of non-beneficial clinical research with children.

Authors:  Eva De Clercq; Domnita Oana Badarau; Katharina M Ruhe; Tenzin Wangmo
Journal:  Med Health Care Philos       Date:  2015-08

3.  Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews.

Authors:  April V P Clyburne-Sherin; Pravheen Thurairajah; Mufiza Z Kapadia; Margaret Sampson; Winnie W Y Chan; Martin Offringa
Journal:  Trials       Date:  2015-09-18       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.